INBX - Company ID 0001739614
The table below shows Inhibrx, Inc.'s cash flow statement line items across its last 5 fiscal years, exactly as reported in the company's audited annual filings. All figures are in US dollars; negative values appear in red.
| Line item | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
|---|---|---|---|---|---|
| Operating cash flow | -$193.31M | -$115.30M | -$80.32M | -$47.97M | -$32.08M |
| Capital expenditure | $4.59M | $686.00K | $864.00K | $1.36M | $1.81M |
| Investing cash flow | -$4.59M | -$686.00K | -$809.00K | -$1.36M | -$1.81M |
| Dividends paid | - | - | - | - | - |
| Stock buybacks | - | - |
Inhibrx, Inc. reported operating cash flow of -$193.31M for fiscal year 2023. That is down 67.7% from -$115.30M in fiscal 2022. Over the 5 fiscal years shown, operating cash flow declined from -$32.08M (FY 2019) to -$193.31M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Financing cash flow | $201.96M | $258.55M | $83.77M | $166.46M | $43.33M |